(redirected from troponin I)
Also found in: Medical, Acronyms, Encyclopedia, Wikipedia.
Related to troponin I: Troponin T


 (trō′pə-nĭn, trŏp′ə-)
A calcium-regulated protein, composed of three subunits, that is found in skeletal and cardiac muscle and regulates contraction by interacting with tropomyosin to control the binding of myosin to actin. Blood troponin levels are a biomarker for muscle damage, as in myocardial infarction.

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.


a protein in muscle tissue that with tropomyosin is involved in the controlling of muscle contraction
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014


(ˈtroʊ pə nɪn, ˈtrɒp ə-)

a protein of muscle tissue that binds calcium ions and is involved in contraction.
[1965–70; tropo(myosin) (see tropo-, myosin)]
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
Cardiac troponin [cardiac troponin I (cTnI) and cTnT] has become globally recognized as the standard biomarker for the diagnosis of acute myocardial infarction (AMI).
27 September 2013 - Beckman Coulter Inc, part of US Danaher Corporation (NYSE:DHR), said Thursday it had received 510(k) approval from the US FDA for its Access AccuTnI+3 troponin I assay for use on the UniCel DxI series of immunoassay systems.
In 14 patients (29%), myocardial damage was classified as significant based upon an admission cardiac troponin I greater than 0.6 ng/mL.
Direct comparison of high-sensitivity-cardiac troponin I vs.
20 June 2013 - Beckman Coulter Inc, part of Danaher Corporation (NYSE:DHR), said on Wednesday it had obtained US FDA 510(k) clearance for its new Access AccuTnI+3 troponin I assay for use on its Access 2 immunoassay system.
In a prospective study of 118 consecutive cases of acute pericarditis treated over 2 years, the researchers assessed cardiac troponin I levels obtained from venous blood samples within 24 hours of symptom onset.
using pooled data from 5 cohort studies recently reported lower sensitivities for both high-sensitivity troponin T at 94.8% (95% CI 89.6%-97.9%) and high-sensitivity troponin I at 93.2% (95% CI 87.5%-96.8%) measured at presentation and at 3 h, raising further questions about the safety of this approach in clinical practice (21).
These findings suggest that high serum levels of troponin I may be a good way to identify patients who have a pulmonary embolism (PE) and could benefit from aggressive throm-bolysis, Dr.
Neumann, M.D., from the University Heart Center Hamburg in Germany, and colleagues determined the concentrations of high-sensitivity troponin I or high-sensitivity troponin T in 15 international cohorts of patients with symptoms suggestive of myocardial infarction; troponin was measured at presentation to the emergency department and after early or late serial sampling.
A total of 1,599 patients in the SUMMIT trial had a baseline cardiac troponin I assessment, and 1,258 had a follow-up assessment at 3 months following randomization.
When a patient experiences chest pains, a blood test can determine if troponin is present.
Cardiac troponin I (cTnl) and T (cTnT) have a high sequence homology across phyla and are sensitive and specific markers of myocardial damage; Homology between canine and feline genes and humans was 95 and 96 percent, respectively (Burgener et al., 2006; Wells and Sleeper, 2008).